TopoTarget establishes TopoTarget USA, Inc. and employs experienced marketeer as President

17-Nov-2006

TopoTarget A/S announced the establishment of TopoTarget USA, Inc. to be located in Rockaway, New Jersey near the center of the east coast U.S. pharmaceutical industry. TopoTarget USA, Inc. is scheduled to launch the company's first oncology product, Totect(TM), for the treat-ment of anthracycline induced extravasations in the first half of 2007.

TopoTarget selected John L. Parsons Jr., a veteran of the pharmaceutical industry, with 30 years of experience, to head the U.S. division. According to the company, his commercial experience spans most therapeutic areas, including oncology, and more than 20 successful product launches. Most recently, through his consulting company, Parsons Strategic Associates, John has been working closely with biotech companies in building commercial infrastructure to bring their products to market. In 2000, as Vice President of Emerging Markets at Quintiles, he worked with CV Therapeutics to launch Ranexa(TM). Most recently, he worked with Enzon Pharmaceuti-cals to build its commercial infrastructure to market specialty pharmaceutical products.

TopoTarget USA plans to launch its first product through its own sales force supplemented by outsourced resources for distribution. This announcement does not change TopoTarget's financial expectations for full-year 2006.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance